ArticleInternational journal of general medicine2026
A Machine Learning-Based Model for Cirrhosis Risk Stratification Incorporating Noninvasive Markers and Clinical Variables.
Article in International journal of general medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: This study aimed to develop and validate a nomogram model integrating routine laboratory parameters, non-invasive fibrosis markers, and liver elastography parameters for cirrhosis risk stratification in patients with chronic liver disease. Methods: A total of 344 patients with chronic liver disease were retrospectively enrolled and randomly divided into a training set (n=241) and a validation set (n=103) in a 7:3 ratio. Independent predictors were identified using univariate analysis, LASSO regression, and multivariate logistic regression. Machine learning algorithms, including Random Forest, Support Vector Machine, and Logistic Regression were constructed using these predictors. Internal validation was performed using the Bootstrap method. Model performance was evaluated by the area under the receiver operating characteristic curve (AUC), calibration curves, and decision curve analysis (DCA). Results: Multivariable logistic regression identified age, platelet count, aspartate aminotransferase/alanine aminotransferase (AST/ALT) ratio, total bilirubin, abnormal international normalized ratio (>1.2), and liver stiffness measurement as independent predictors of cirrhosis. The Random Forest model demonstrated slightly superior performance, with AUCs of 0.835 (95% CI: 0.767-0.904) and 0.745 (95% CI: 0.597-0.893) in the training and validation sets, respectively. The calibration curves demonstrated good consistency between the predicted probabilities and the actual risks (Hosmer-Lemeshow test, P > 0.05). Decision curve analysis indicated that the Random Forest model provided a superior net clinical benefit across a threshold probability range of 0.1-0.3. Conclusion: This study developed and validated a cirrhosis risk prediction model. The Random Forest model offers marginally better accuracy, while the nomogram provides a simple, interpretable tool for bedside clinical use. With further external validation, this model could potentially assist clinicians in stratifying cirrhosis risk among patients with chronic liver disease.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.